R

Roche

Global pharmaceuticals and diagnostics company

Instructional Design Advisor

Full-TimeUpdated on 10/14/2026
No salary listed
Mid
Bachelor's
Petaling Jaya, Selangor, Malaysia+1 moreMore locations: Budapest, Hungary
In PersonTravel of up to 10%.
TrainingInstructional Design & Curriculum Development

About the job

Requirements
  • Experience in a shared service center, preferably in a Learning or HR services environment.
  • Experience with Cornerstone or other cloud-based learning management solutions.
  • Attention to detail, a creative mind, and storytelling skill.
  • Learning and development know-how; knowledge of eLearning processes is an advantage.
  • Strong customer service and interpersonal skills.
  • Excellent communication skills and ability to work as a team member.
  • Problem-solving and analytical abilities.
  • A proven track record of delivering in a matrix organization.
  • Ability to work independently in a fast-paced environment and handle multiple competing priorities.
  • Ability to work across borders in an ambiguous and multicultural environment.
  • Experience working effectively in a matrix organization across geographies and divisions.
  • Ability to navigate complex Learning data structures.
  • Ability to work in a fast-paced and changing environment.
  • Experience producing, directing, and editing audiovisual content, including graphic and video content.
  • A bachelor's degree is required.
  • At least 2 years of experience in instructional design.
  • At least 2 years of experience with e-content authoring tools such as Adobe Captivate, Articulate Presenter, Articulate Storyline, or Lectora.
  • Fluency in English is required; additional languages may be advantageous depending on region, including German, French, Italian, Spanish, Portuguese, Hungarian, or Chinese.
  • Demonstrated excellence in customer service and partnership building.
  • Ability to communicate effectively verbally and in writing and to influence people.
  • Strong functional knowledge of eLearning concepts such as SCORM, AICC, and ADDIE.
  • Strong analytical and problem-solving capability.
  • Strong project management skills.
  • Quality focus and ability to analyze and interpret testing outcomes and apply the results.
  • Willingness to travel up to 10%.
  • Experience leading instructional design development projects within the pharmaceutical or medical device industry.
  • Experience training or coaching other instructional design professionals.
  • Solid experience with digital technology and editing software packages such as Adobe Creative Suite, Adobe Premiere, and Adobe After Effects.
Responsibilities
  • Analyze learning needs and partner with internal customers to provide input for course content.
  • Plan, organize, and develop training content to meet specific training needs.
  • Use authoring tools and software to create e-content from scratch and modify existing e-content.
  • Create high-quality, well-functioning eLearning courses.
  • Identify and troubleshoot reported issues before escalation to Tier 3 or IT support.
  • Assist with implementation and further evaluation of course content.
  • Work on complex assignments and issues and serve as an expert in eLearning trends.
  • Provide customer service for eLearning activities, including inquiry resolution, request management, and troubleshooting.
  • Support the Global Learning Center of Excellence and business customers with system maintenance and project activities.
  • Advise the Learning community and business partners on global Learning systems and processes, and support embedding new ways of learning.
  • Participate in the development and implementation of Roche Learning continuous improvement initiatives.
  • Participate in workshops, meetings, and work-related team events.
  • Provide guidance and advice to the Learning community at all levels.
  • Maintain up-to-date process knowledge, own process knowledge development, and contribute to updating relevant documentation, including SWIs, SOPs, and GWIs.
  • Support quality control processes and related improvement initiatives.
  • Ensure consistent and reliable service delivery for customers.
  • Contribute to process superuser activities, including community participation, information sharing, issue escalation, and training delivery.
  • Participate in and partially lead project activities as required.
  • Comply with Roche guidelines, including data privacy rules and regulations.
  • Implement processes and initiatives to ensure continuous improvement and service enhancement.
  • Align service delivery and quality with the objectives of the global HR Support Solutions organization.
  • Manage service quality expectations and address customer concerns.
  • Own resolution end to end.
  • Ensure operations meet defined KPIs and SLAs.
  • Develop and manage key stakeholder relationships and communications to support proactive, customer-outcome-focused partnerships.
  • Deliver all content projects on time and predictably.
  • Build relationships with HR colleagues and customers to ensure ongoing service delivery effectiveness.
  • Collaborate with regional and global peers to provide consistent and effective services across the People Support Solutions network.
  • Drive global consistency through collaboration.
  • Contribute continuously to improving PSS performance and achieving high customer satisfaction through consistent, high-quality delivery and customer care principles.
  • Provide feedback, coaching, and advice to contacts in HR and the business.
  • Create explainer videos and educational content.
Desired Qualifications
  • Experience in a shared service center, preferably in a Learning or HR services environment.
  • Knowledge of eLearning processes.
  • Additional languages depending on region, including German, French, Italian, Spanish, Portuguese, Hungarian, or Chinese.

About the company

Roche is a global leader in pharmaceuticals and diagnostics. It develops medicines and diagnostic tools that help detect, monitor, and treat diseases, using research and biotechnology to drive new therapies and tests. Roche combines drug development with in-house diagnostic products to support personalized medicine, where treatments are tailored to individual patients based on test results. Its approach differs from many peers by integrating drug discovery with diagnostic capabilities and by expanding its research through strategic acquisitions (like Genentech) to strengthen its biotechnology and R&D capabilities. The company’s goal is to improve patient outcomes and healthcare worldwide by delivering reliable medicines, accurate diagnostic tests, and data-driven care.

Company Size

1-10

Company Stage

IPO

Headquarters

Basel, Switzerland

Founded

1896

Get referred to Roche

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Enicepatide delivered 15.5% weight loss in September 2026 and 22.7% in June.
  • pTau217 can scale immediately through Roche's existing lab network and improve Alzheimer diagnostics.
  • Roche's June 2026 data and September 2026 filings signal multiple obesity shots on goal.

What critics are saying

  • Eli Lilly and Novo Nordisk dominate obesity pricing, distribution, and physician mindshare today.
  • Enicepatide remains Phase II-only; Roche starts late-stage glycemic and cardiovascular studies in 2027.
  • If enicepatide disappoints, Roche burns its $2.7 billion Carmot bet and loses obesity credibility.

What makes Roche unique

  • Roche combines pharma, diagnostics, and installed cobas labs across 4,500 U.S. instruments.
  • Elecsys pTau217 won FDA clearance on August 24, 2026, and CE marking September 7.
  • Roche controls obesity assets from Carmot and Zealand, spanning GLP-1/GIP and amylin.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Performance Bonus

Company News

Yahoo Finance
Oct 9th, 2026
FDA approves Roche's Tecentriq for stage III colon cancer, cutting recurrence risk by 50%

The US Food and Drug Administration has approved Roche's Tecentriq in combination with a fluoropyrimidine and oxaliplatin for adjuvant treatment of stage III deficient DNA mismatch repair colon cancer. This marks Tecentriq's twelfth approved indication in the US. The approval follows the phase III ATOMIC study, published in The New England Journal of Medicine, which demonstrated that Tecentriq plus chemotherapy reduced the risk of disease recurrence or death by 50% compared to chemotherapy alone. The 36-month disease-free survival rate was 86% with the combination versus 76% with chemotherapy alone. Nearly 25% of colon cancers are diagnosed at stage III, and almost one in three stage III patients experience recurrence within five years. This represents the first approved adjuvant immunotherapy regimen for this patient population. Roche is pursuing further regulatory filings, including with the European Medicines Agency.

Yahoo Finance
Sep 30th, 2026
Roche's enicepatide shows 22.5% weight loss in 48 weeks, challenging Eli Lilly and Novo Nordisk

Roche posted strong Phase 2 results for its weight loss drug enicepatide, showing 22.5% mean weight loss over 48 weeks. This compares favourably to Eli Lilly's Zepbound, which achieved 20.2% weight loss over 72 weeks in a separate trial. In another Phase 2 study, enicepatide demonstrated HbA1c reductions of up to 2.65 percentage points in diabetic patients after 48 weeks, compared to tirzepatide's 2.37 percentage points after 52 weeks. Despite promising results, Roche faces stiff competition from Novo Nordisk and Eli Lilly, which both have deep pipelines in development. Novo Nordisk's CagriSema is nearing approval, whilst Eli Lilly's retatrutide has posted strong Phase 3 results. Roche's revenue grew 6% year over year in the first half of the year to 30.4 billion Swiss francs.

PR Newswire
Sep 30th, 2026
Roche launches newborn screening test for SMA, SCID and sickle cell disease

Roche has launched a newborn screening test that simultaneously detects three severe genetic conditions: Spinal Muscular Atrophy, Severe Combined Immunodeficiency Disease, and Sickle Cell Disease. TIB MOLBIOL, a Roche subsidiary, developed the LightMix Newborn TREC/SMN1/HBB kit for use in countries accepting the CE mark. The test enables early detection before symptoms appear, allowing clinicians to initiate life-changing treatments sooner. Early intervention can prevent severe nerve damage in SMA, enable lifesaving bone marrow transplants for SCID, and drastically lower infant mortality in SCD through preventive measures. The IVDR-approved test provides a ready-to-use solution that integrates into existing laboratory workflows. It runs on established LightCycler systems, making it accessible for private and academic hospital laboratories across Europe.

Yahoo Finance
Sep 13th, 2026
Roche's Tam-Peli cuts death risk by 54% in Chinese SCLC trial, global phase III studies planned

Roche's collaborator MediLink has announced positive phase III results for tambotatug pelitecan (Tam-Peli) in Chinese patients with relapsed small-cell lung cancer. The TAISHAN-302 trial showed Tam-Peli reduced the risk of death by 54% compared to topotecan, with median overall survival of 13.3 versus 9.4 months. The antibody-drug conjugate also demonstrated superior progression-free survival (7.4 versus 2.8 months) and objective response rates (59.1% versus 9.7%). China's National Medical Products Administration has accepted the New Drug Application for filing. Roche is developing and commercialising Tam-Peli outside mainland China, Hong Kong and Macau, with plans to rapidly initiate global trials. The therapy has received Breakthrough Therapy Designations from both the US FDA and China CDE for relapsed small-cell lung cancer.

World Today News
Sep 8th, 2026
Tempus AI raises $600M to scale AI-enhanced liquid biopsy platform for cancer recurrence detection

Tempus AI has raised $600 million in Series C funding to scale its machine learning platform for cancer recurrence detection through liquid biopsies. The investment was led by SoftBank Vision Fund 2, with participation from Roche and Merck. Phase II trial data showed the AI-enhanced liquid biopsy analysis reduced false-negative results by 37% compared to conventional methods. The platform uses deep learning algorithms trained on over 12,000 genomic profiles to identify circulating tumour DNA fragments shed by residual cancer cells. A 2025 Nature Medicine study reported the system achieved 92% specificity in detecting minimal residual disease across breast, lung, and colorectal cancers. According to SEC filings, 45% of funds will support FDA pre-market approval trials, whilst 30% will fund global expansion into EU and APAC markets.